

CIDARA THERAPEUTICS UK LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2023

CIDARA THERAPEUTICS UK LIMITED
REGISTERED NUMBER: 10054750

BALANCE SHEET
AS AT 31 DECEMBER 2023

	Note	2023 £	2022 £
Total assets less current liabilities		-	-
Net assets		<u>-</u>	<u>-</u>
Capital and reserves		<u>-</u>	<u>-</u>

For the year ended 31 December 2023 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

S Ward
Director

Date: 3 March 2024

The notes on page 2 form part of these financial statements.

CIDARA THERAPEUTICS UK LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1. GENERAL INFORMATION

Cidara Therapeutics UK Limited is a Company limited by shares incorporated in the United Kingdom. The registered number is 10054750 and its registered office address is 3rd Floor 1 Ashley Road, Altrincham, Cheshire, United Kingdom, WA14 2DT. This company is part of a group.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

3. EMPLOYEES

The average monthly number of employees, including directors, during the year was 0.

4. SHARE CAPITAL

	2023 £	2022 £
Allotted, called up and fully paid		
100 (2021 - 100) Ordinary shares of £0.0001- each	<u>-</u>	<u>-</u>

5. CONTROLLING PARTY

As at the date of approval of these accounts, the Company's direct and ultimate parent company is Cidara Therapeutics Inc, incorporated in the United States of America.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.